| HOME >> BIOLOGY >> TECHNOLOGY |
7,692,0581,033,102Cash flows from investing activities:Additions to property and equipment
(241,885)(311,301)Additions to patents
(140,356)(132,047)Net cash used in investment activities
(382,241)(443,348)Cash flows from financing activities:Principal payments on note payable
(5,333,333)(12,000,000)Net borrowings on line of credit
2,750,000-Costs of financing for long-term debt and credit facility
-(82,500)Proceeds from exercise of stock options
681,6341,182,139Excess tax benefit derived from exercise of stock options
2,657,2591,256,913Repurchase of common shares
(2,884,540)(4,129,648)Net cash used in financing activities
(2,128,980)(13,773,096)Net increase (decrease) in cash and cash equivalents
5,180,837(13,183,342)Cash and cash equivalents at beginning of period
65,893,97078,701,682Cash and cash equivalents at end of period
$
71,074,807$
5,518,340Supplemental disclosure of cash flow information:Non-cash investing and financing activities:Common shares repurchased during period but not paidas of the end of the period
-22,207
'/>"/>
| SOURCE Cumberland Pharmaceuticals Inc. Copyright©2010 PR Newswire. All rights reserved |